- Home
- OEC vs TYRA Comparison
OEC vs TYRA Comparison
Compare OEC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OEC
- TYRA
- Stock Information
- Founded
- OEC 1862
- TYRA 2018
- Country
- OEC Luxembourg
- TYRA United States
- Employees
- OEC N/A
- TYRA N/A
- Industry
- OEC Major Chemicals
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- OEC Industrials
- TYRA Health Care
- Exchange
- OEC Nasdaq
- TYRA Nasdaq
- Market Cap
- OEC 674.8M
- TYRA 576.6M
- IPO Year
- OEC 2014
- TYRA 2021
- Fundamental
- Price
- OEC $11.06
- TYRA $9.67
- Analyst Decision
- OEC Buy
- TYRA Strong Buy
- Analyst Count
- OEC 2
- TYRA 7
- Target Price
- OEC $13.50
- TYRA $30.86
- AVG Volume (30 Days)
- OEC 586.6K
- TYRA 419.0K
- Earning Date
- OEC 07-31-2025
- TYRA 08-06-2025
- Dividend Yield
- OEC 0.78%
- TYRA N/A
- EPS Growth
- OEC N/A
- TYRA N/A
- EPS
- OEC 0.46
- TYRA N/A
- Revenue
- OEC $1,852,300,000.00
- TYRA N/A
- Revenue This Year
- OEC N/A
- TYRA N/A
- Revenue Next Year
- OEC $4.76
- TYRA N/A
- P/E Ratio
- OEC $23.30
- TYRA N/A
- Revenue Growth
- OEC N/A
- TYRA N/A
- 52 Week Low
- OEC $9.59
- TYRA $6.42
- 52 Week High
- OEC $24.85
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- OEC 44.73
- TYRA 46.24
- Support Level
- OEC $10.41
- TYRA $9.03
- Resistance Level
- OEC $10.88
- TYRA $9.96
- Average True Range (ATR)
- OEC 0.37
- TYRA 0.65
- MACD
- OEC 0.01
- TYRA -0.06
- Stochastic Oscillator
- OEC 26.93
- TYRA 23.65
About OEC Orion S.A.
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing and special applications. Geographically, it derives a majority of its revenue from Germany.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.